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Two hepatotropic viruses, hepatitis B and C viruses, are known to cause hepa-
tocellular carcinoma in humans. Hepatocarcinogenesis is a complex, stepwise
process that evolves over several to many years and precisely how hepatitis
viruses contribute to malignant transformation of hepatocytes is uncertain.
Hepatitis B vrus is integrated into cellular DNA in the great majority ofhepati-
tis B virus-related hepatocellular carcinomas, whereas replicative intermediates
ofhepatitis C virus do not insert into chromosomal DNA, making it likely that
different pathogenetic mechanisms operate with the two viruses. Indeed, evi-
dence is mounting that both direct and indirect carcinogenic mechanisms, and
often the two together, are involved in virus-induced hepatocellular carcinoma.
In addition, evidence is now available that hepatitis B and C viruses interact
synergistically in the pathogenesis ofhepatocellularcarcinoma. Animal models,
- other members of the Hepadnaviridae family that cause tumors in their
respecitve animal hosts, and transgenic mice into which the sequences of
hepatitis B virus DNA have been inserted - are proving useful in elucidating
putative mechanisms of hepatitis B virus-related hepatocarcinogenesis.
Whatever the genesis of hepatitis virus-induced hepatocellular carcinoma, it is
clear that hepatitis viruses do not act alone but in conjunction with other envi-
ronmental carcinogens and a number ofhost factors.
INTRODUCTION
Of the six human hepatitis viruses now recognised, hepatitis A and E viruses do not
exist in a chronic carrier state and cause acute infections only: they are not risk factors for
hepatocellular carcinoma (HCC)b. In contrast, hepatitis B and C viruses do exist in a
chronic carrier state and are frequent causes of chronic necroinflammatory hepatic dis-
ease: they are major risk factors for human HCC. Although hepatitis D virus always
occurs in tandem with hepatitis B virus and co-infection causes severe acute and chronic
hepatic parenchymal disease, there is no convincing evidence that this virus contributes to
hepatocarcinogenesis. Little is yet known about the newly identified hepatitis G (GB-C)
virus. From the way in which it was detected, however, it is evident that chronic carriage
does occur, and there is preliminary evidence that it causes chronic liver disease. A pilot
study has shown this virus to be present in the serum of4 of 14 patients with HCC.
The evidence for hepatitis B and C viruses as hepatocarcinogens will be reviewed.
aTo whom all correspondence should be addressed: Professor M.C. Kew, Department of Medicine,
Witwatersrand University Medical School, 7 York Road, Parktown 2193, Johannesburg, South
Africa. Tel.: 27-11-488-3626; Fax: 27-11-643-4318.
bAbbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus;
WHV, woodchuck hepatitis virus; GSHV, ground squirrel hepatitis virus; anti-HCV, antibody to
hepatitis C virus.
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HEPATITIS B VIRUS AND HEPATOCELLULAR CARCINOMA
Evidencefor hepatocarcinogenicity
Chronic infection with HBV has been estimated to be responsible for up to 80 per-
cent of global HCC. The first evidence, albeit circumstantial, of a possible link between
HBV and HCC was the close parallel, at both global and local levels, between the geo-
graphical distributions of viral carriage and that of the tumor [1-3]. A causal association
between HBV and HCC was soon confirmed by the cohort study ofBeasley and co-work-
ers [3] in which male Taiwanese carriers of the virus were shown to have a lifetime rela-
tive risk for developing the tumor of more than 100. Between 40 and 50 percent of these
carriers, and 25 percent of those in other populations, die from HCC, cirrhosis, or both
diseases. At the same time numerous studies from all parts of the world, irrespective of
whether the incidence of HCC was high, intermediate, or low, demonstrated that patients
with this tumor invariably showed serum and liver tissue markers ofpersistent HBV infec-
tion far more often than did control populations [1-3]. The closest correlations were pre-
sent in ethnic Chinese and black Africans, in whom as many as 85 percent of the patients
were currently infected with HBV at the time they presented with HCC and almost all of
the remainder showed evidence ofprevious infection. In these populations HBV carriage
is largely acquired early in life as a result of either perinatal infection, in ethnic Chinese
[3], or horizontal infection, in blackAfricans [4]. It is these early-onset carriers that are at
greatest risk ofHCC formation. The risk for those infected later in life has been less clear-
ly defined, but it is substantially less than for those with early infection. HBV carriage
almost always precedes the development of HCC by many years, an interval consistent
with a cause-and-effect relationship, and the likelihood of malignant transformation rises
progressively with increasing duration of infection.
The great majority of HBV-related HCCs have sequences of viral DNA integrated
into chromosomal DNA [5].
Indirect evidence for a causal relation between HBV and HCC is provided by the
observation that other members of the Hepadnaviridae (to which HBV belongs) also
induce HCC in their respective hosts: in eastern woodchucks (Marmota monax) infected
withWHV with a frequency ofvirtually 100 percent within about 2 years ofinfection, and
in Beechey ground squirrels infected with GSHV ofapproximately 30 percent within 5 to
6 years [6, 7]. Integrants ofhepadnaviral DNA have been detected in both ofthese animal
models. More recently, transgenic mice that developed HCC after sequences of the HBV
genome were introduced into their germ-lines have provided further indirect evidence of
the hepatocarcinogenicity of HBV [8, 9].
Possible mechanisms ofHBV-induced hepatocarcinogenicity
Although the exact mechanisms involved in HBV-induced HCC remain uncertain,
there is mounting evidence that both direct and indirect carcinogenic effects are operative.
Directcarcinogenicity: The observations thatHBV-induced HCC can occur in an oth-
erwise normal liver and that markers of HBV infection are present in serum and liver tis-
sue as often in HCC patients without co-existing cirrhosis as in those with cirrhosis first
suggested that HBV may be directly carcinogenic. This possibility was later supported by
the findings both that 85 to 95 percent ofHBV-related (and WHV-related) tumors contain
viral DNA integrants in host DNA [5], and that transgenic mice into which the HBx gene
and its regulatory sequences had been inserted develop HCC in the absence ofcirrhosis or
chronic hepatitis [9].
Early on, the long interval between infection with HBV and the onset ofHCC implied
that the virus did not contain an an acutely transforming oncogene, and this was subse-
quently confirmed when the viral genome was completely sequenced. The finding ofviral
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integrants in host DNA in HCC tissues made it probable that HBV exerts its carcinogenic
effect through insertional mutagenesis. HBV DNA appears to integrate into chromosomal
DNA at random sites [5], and it is therefore unlikely that insertion is exerting an effect in
cis. Indeed, in three human tumors only has HBV DNA been shown to integrate in or near
the regulatory sequences of a known proto-oncogene [10, 11] and in none has integration
disrupted a recognised tumor suppressor gene. Moreover, fusion proteins composed of
HBV- and cellular gene- products have not been detected. Nevertheless, indirect support
for this possible mechanism is provided by the finding that in about 50 percent of wood-
chucks infected with WHV insertion of WHV DNA takes place within regulatory
sequences of c-myc or N-myc 2, activating expression of these genes. Activation ofc-jun
and c-fos has also been described in a number of these tumors. Furthermore, transgenic
mice develop HCC after the woodchuck c-myc gene in tandem with upstream WHV DNA
has been incorporated into their germ-line. When ground squirrels infected with GSHV
were studied, however, none ofthe integrants proved to be near c-myc or N-myc 2, mak-
ing the overall interpretation of this possible mechanism difficult to evaluate. Moreover,
in the transgenic model of Chisari and co-workers [8] expression analysis of all proto-
oncogenes and tumor suppressor genes thus far implicated in hepatocarcinogenesis failed
to reveal any quantitative or qualitative changes [12].
An effect in trans is, however, possible. The HBx gene can transactivate transcription
of a variety of viral and cellular promoters [13], thereby perturbing the expression ofcel-
lular growth regulatory genes and hence the function of the infected cell in such a way as
ultimately to induce a transformed phenotype. Support for this mechanism was provided
by introducing HBx gene and its regulatory sequences into the germ-line of mice. The
progeny developed, in turn, foci of altered hepatocytes, benign tumors, and finally florid
HCCs, all in the absence of chronic hepatic parenchymal disease [9]. The HBV preS/S
gene has also been shown, when 3'-truncated, to possess transactivating properties [14].
Both of these genes, but particularly the x gene, are often included in HBV DNA inte-
grants, and could express HBV polypeptides or possibly HBV-cellular gene fusion pro-
teins.
Loss or disruption of chromosomal DNA in the sequences flanking integrated HBV
DNA may result in deletion oftumor suppressor genes or, by altering the physical relation
between proto-oncogenes or tumor suppressor genes and their regulatory sequences,
either remote from or adjacent to the site of insertion, may affect expression of these
genes.
These observations suggest that abnormal expression of cellular genes may initiate
aberrant growth. The HBx gene has been shown to interact in vitro with the p53 protein
causing inhibition ofp53-mediated transcriptional regulation [15]. An effect on apoptosis
could possibly be mediated in the same way. Activation or inactivation of growth regula-
tory genes, whether in cis or in trans, remains an attractive hypothesis because either
could confer on initiated hepatocytes a growth advantage that, coupled with an opportu-
nity for selection, would generate cells that are at risk for further genetic or epigenetic
events in the stepwise process required for tumor formation.
Although integration of viral DNA into host DNA is likely to play a pivotal role in
HBV-induced HCC, it has not yet been proved to be an essential step in the process. Nor
is it known when and precisely how integration takes place. Whether HBV can cause
HCC in the absence of other environmental carcinogens is also uncertain. The most con-
vincing evidence that it can are the observations that woodchucks infected with WHV as
neonates and reared in an environment free ofknown carcinogens develop HCC [16], and
that HBsAg-positive mentally disabled children living in California, USA in the appar-
ent absence ofcarcinogens are at are at very high risk ofdeveloping this tumor [17]. Of
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additional significance is the fact that in both of these circumstances the tumors develop
in the absence of cirrhosis.
Indirect carcinogenicity: Most patients with HCC, whether in regions with high, low,
or intermediate incidence regions of the tumor, have co-existing cirrhosis (a few have co-
existing chronic hepatitis) [18]. Moreover, cirrhosis, whatever the cause, may be compli-
cated by malignant transformation [18]. These observations lend support to the beliefthat
HBV can induce HCC indirectly by causing chronic necroinflammatory hepatic disease.
This mechanism would also explain the high incidence ofHCC in patients with membra-
nous obstruction ofthe inferior vena cava, in whom unremitting hepatic venous hyperten-
sion causes continuous cell necrosis and regeneration, as well as those patients with HBV-
related HCC in whom viral integrants are not detected. A likely way in which chronic
necroinflammatory hepatic disease could contribute to carcinogenesis would be by func-
tioning as a promoter. Continuous or recurring cycles ofnecrosis ofhepatocytes followed
by regeneration, as typically occurs in cirrhosis or chronic hepatitis, renders the hepato-
cyte DNA far more susceptible both to spontaneous mutation and to exogenous damage.
Furthermore, an increased hepatocyte turnover rate may, by increasing the intracellular
concentration and activity of topoisomerase I, result in cleavage of viral DNA at specific
motifs, thereby promoting its integration into chromosomal DNA [19]. More rapid cell
division may also leave insufficient time for damaged DNA to be repaired before the cell
divides again, thereby "fixing" the altered DNA in the daughter cells. In addition,
increased hepatocyte division provides the opportunity for the selective growth advantage
of initiated cells to be exercised.
Indirect evidence in favor of a role for necroinflammatory hepatic disease in the
pathogenesis of HCC is provided by transgenic mice into which the HBV S and preS
genes have been introduced [8]. The progeny overproduce large surface protein that accu-
mulates in the smooth endoplasmic reticulum of the hepatocytes, producing severe and
prolonged injury to the cells, which initiates a response characterised by inflammation,
regenerative hyperplasia, and transcriptional deregulation, and which progresses ultimate-
ly to neoplasia. These findings imply that severe and prolonged injury per se may lead to
unrestrained cell growth. This conclusion was supported by the subsequent expression
analysis, in this model, ofall proto-oncogenes and tumor suppressor genes implicated in
hepatocarcinogenesis, which failed to reveal any quantitative or qualitative changes [12].
Like all forms of carcinogenesis, hepatocellular carcinogenesis is a complex multi-
step process that evolves over many years. Different pathways of tumor induction, direct
or indirect, probably operate in different HBV-related HCCs. Moreover, direct and indi-
rect mechanisms are not mutually exclusive, and the two acting in concert may be respon-
sible for most HBV-induced HCCs.
HEPATITIS C VIRUS AND HEPTOCELLULAR CARCINOMA
Evidence for an etiological role for hepatitis C virus (HCV) in HCC is more recent
but is nonetheless persuasive. The first hint of a link between this virus and the tumor
came from isolated reports in the literature of patients (and one chimpanzee) with acute
non-A, non-B hepatitis following blood transfusion who, over a period of many years,
developed in turn chronic hepatitis, cirrhosis, and finally HCC [20]. Stored sera from
some ofthese patients (but not the chimpanzee) were subsequently shown to test positive
for anti-HCV. More substantive evidence was provided later by case series, case/control
analyses, and cohort studies that used progressively more reliable enzyme immunoassays,
confirmatory recombinant immunoblot assays, and reverse transcription-polymerase
chain reaction to detect HCV infection. The International Agency for Research on Cancer
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ofthe World Health Organisation has recently concluded that HCV, like HBV, is carcino-
genic in humans [21].
As is true ofHBV, the proportion ofpatients with HCC in whom HCV can be impli-
cated shows a pronounced geographical variation [20, 21]. In Japan, with ahigh incidence
of HCC, and Italy and Spain, with intermediate incidences, as many as 80 percent of
patients with HCC are infected with HCV, and persistent HCV is a greater risk of HCC
than is chronic HBV infection. In these countries 2 to 3 percent of patients with HCV-
related cirrhosis develop HCC during each year offollow-up. In contrast, in those regions
in which HBV infection is hyperendemic and HCC very common, fewer than 25 percent
of patients have HCV-related tumors. In the remaining countries, with low or intermedi-
ate incidences ofHCC, HCV and HBV play an equal but relatively minorrole, with mark-
ers of each virus being found in about one-quarter ofthe patients.
Patients with HCV-induced HCC are, in almost all geographical regions, older than
patients with HBV-induced tumors; the difference in blackAfricans is about 20 years and
in other populations around 10 years [20].
Possible mechanisms ofHCV-induced HCC
Replicative intermediates of HCV, a single-stranded RNA virus of positive polarity,
do not integrate into chromosomal DNA, although the virus does replicate in both normal
and malignant hepatocytes [22]. If HCV is directly carcinogenic, therefore, the mecha-
nism is likely to differ from that of HBV. Until very recently there was no well docu-
mented evidence that HCV-induced HCC occurred in livers that were not either cirrhotic
or showed chronic hepatitis. However, DiMitri and co-workers have now reported exam-
ples of HCV-related tumors developing in virtually normal livers, providing the first cir-
cumstantial evidence that this virus might be capable of directly inducing neoplastic
change [23].
On the other hand, the very marked propensity for acute HCV infections to progress
to chronic liverdisease (with afrequency now approaching 80 percent), as well as the very
close link between HCV-related HCC and cirrhosis (or less often chronic hepatitis) strong-
ly supports an indirect role for the virus in the pathogenesis of HCC. The importance of
an increased hepatocyte turnover rate in HCV-induced HCC was recently emphasised in
reports in which the risk of the tumor developing in patients with HCV-related chronic
necroinflammatory hepatic disease correlated directly with high DNA synthetic activity as
a marker of proliferative activity [24].
Interaction between HBVand HCV in hepatocarcinogenesis
Knowing whether HBV and HCV interact in the origin of HCC might help in eluci-
dating the pathogenetic mechanisms involved in virally-induced hepatocarcinogenesis.
Although HBV and HCV are separately major risk factors for HCC, the risk when co-
infection with the two viruses occurs is uncertain. Four analyses have been published in
which possible confounding influences ofother variables have been taken into account in
establishing the odds ratio for the development of HCC in individuals chronically infect-
ed with HBV alone, HCV alone, and the two viruses together. Two studies, one in Taiwan
(which has a high incidence of HCC) [25], the other in Italy (which has an intermediate
incidence) [26] showed no interaction between HBV and HCV as hepatocarcinogens. The
other two, in populations with a low incidence ofHCC, revealed an interactive effect, one
additive (in North American patients) [27] and one multiplicative (in Greek patients) [28].
In a recent case/control study of231 southern African blacks with HCC (a high incidence
region for HCC), we demonstrated a synergistic interactive effect between the two virus-
es [29].
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Indirect support for an interactive carcinogenic role between the two viruses comes
from our observation that patients infected with both HBV and HCV are significantly
younger than those infected with HCV alone. How HBV and HCV interact in the genesis
of HCC is not known. Patients with dual infection react to HCV antigens alone (or pre-
dominantly), suggesting that HCV infection plays the dominant role in the immune
response in patients infected with both viruses [30]. If this observation is confirmed, the
promoter effect ofcombined HBV and HCV infection in hepatocarcinogenesis should be
no greater than that with either virus alone. The evidence that HBV and HCV interact in
the origin of HCC would then imply that HCV, like HBV, is capable of being directly
oncogenic.
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